The latest medical research on Haematology

The research magnet gathers the latest research from around the web, based on your specialty area. Below you will find a sample of some of the most recent articles from reputable medical journals about haematology gathered by our medical AI research bot.

The selection below is filtered by medical specialty. Registered users get access to the Plexa Intelligent Filtering System that personalises your dashboard to display only content that is relevant to you.

Want more personalised results?

Request Access

Naturally Occurring Anti-D in a Male Blood Donor, Unresolved Mystery.

Indian Journal Hematology Blood Transfusion

In accordance with numerous national and international criteria, screening donated blood for abnormal antibodies against red cell antigens is cruci...

CSE1L Silencing Enhances Cytarabine-mediated Cytotoxicity in Acute Myeloid Leukemia.

Indian Journal Hematology Blood Transfusion

This study aims to investigate the increased toxicity of Cytarabine (Ara-c) by knockdown of chromosome segregation 1-like (CSE1L) in acute myeloid leukemia(AML) cells(Kasumi-1, U937, and THP-1 cells) and to explore its possible mechanisms.

Target gene silencing was achieved using the shRNA-mediated lentivirus method. Apoptosis was identified using the Annexin V PE/7-AAD double-staining assay. Cell viability was assessed with the Cell Counting Kit-8 (CCK-8) assay. Protein expression was detected by Western blotting.

In vitro, knocking down CSE1L promoted caspase-3 and caspase-9 proteins expression and induced apoptosis in AML cells. Knockdown of CSE1L enhanced AML cells' sensitivity to Ara-c. knockdown of CSE1L reduced the expression levels of p-JKA2 and p-STAT3 proteins, while no significant difference was observed in the expression levels of total JAK2 and STAT3 proteins. Furthermore, JAK2 overexpression reversed the increase in Ara-c toxicity to AML cells caused by CSE1L knockdown.

In conclusion, our study reveals that CSE1L is a potential therapeutic target for overcoming Ara-c resistance in AML cells. Thus, we have gained new insights into the oncogenic process of CSE1L in AML cells and raised the prospect of knockdown of CSE1L in AML in combination with cytarabine-targeted therapy.

Association of Secretor And Nonsecretor Status with Lewis Phenotyping Among Blood Donors: A Prospective Observational Study from Tertiary Care Hospital.

Indian Journal Hematology Blood Transfusion

ABO (ABH) antigen expression on red cell antigens and secretion of ABH substances in body fluids are governed by different genes. The presence or a...

Granulocytapheresis Donor Deferrals Pattern at a Pediatric Tertiary Care Centre in Northern India.

Indian Journal Hematology Blood Transfusion

Granulocyte transfusion is used to manage refractory infections in patients with severe neutropenia. One of the main challenges in providing granul...

Real World Outcomes with Treatment Free Remission in Chronic Myeloid Leukemia-Experience from a Tertiary Care Cancer Centre.

Indian Journal Hematology Blood Transfusion

Chronic myeloid leukaemia (CML) is caused by balanced translocation t(9::22)(q34;q11) resulting in formation of pathogenic BCR-ABL fusion gene. Tyr...

Clinical Profile, Treatment and Outcome of Thrombotic Thrombocytopenia Purpura (TTP) in Rituximab Era- an Experience from Tertiary Care Centre from North India.

Indian Journal Hematology Blood Transfusion

Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic hemolytic anemia (MAHA) resulting from severe deficiency of ADAMTS13. TTP is an acu...

A Case Report of Therapeutic Plasma Exchange in Hypertriglyceridemia-Induced Pancreatitis.

Indian Journal Hematology Blood Transfusion

To support the evidence of plasma exchange's ability to rapidly lower serum TG levels and provide upcoming research opportunities for evaluating th...

Maternal and Foetal Outcomes of Newly Diagnosed Chronic Myeloid Leukemia During Pregnancy and its Long-Term Impact.

Indian Journal Hematology Blood Transfusion

Diagnosing Chronic Myeloid Leukemia (CML) during pregnancy presents challenges for both haematologists and obstetricians. Limited data exists regar...

A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India.

Indian Journal Hematology Blood Transfusion

The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration. Appropriate strategies were applied to mitigate the drug interference, and the transfusion outcome was analyzed by following up with the patients for six months. A total of 48 patients were studied. The antibody screen was negative in patients who presented before the administration of daratumumab (n = 35). Extended phenotyping was done for 31 patients. Blood group genotyping was done for 4 patients. The patients who presented after daratumumab administration (n = 13) had a positive antibody screen that became negative with dithiothreitol-treated cells. A total of 261 red cell units were transfused to these patients (mean 5.55 units per patient). None of the patients developed antibodies during the follow-up period. The transfusion services must frame policies and protocols to mitigate drug interference. Good communication between transfusion services and clinical hematologists is a must to ensure safe transfusions.

The online version contains supplementary material available at 10.1007/s12288-024-01763-5.

Application of Multi-Department Cooperation, Intelligent Prevention, and Supervision to Reduce the Incidence of Central Line-Associated Bloodstream Infections.

Indian Journal Hematology Blood Transfusion

Central line-associated bloodstream infections (CLABSIs) can result in worse outcomes and high hospitalization cost for patients. This study aimed to assess the effectiveness of multi-department cooperation, intelligent prevention, and supervision (MDCIPS) in reducing the incidence of CLABSIs and improving the clinical outcomes of the patients. Key issues were identified through a literature review and survey on the status quo. A MDCIPS model was thus built. A total of 440 patients with indwelling central venous catheters (CVCs) were enrolled in the study. The control group (n = 219) received conventional infection-control managements, while the intervention group (n = 221) received MDCIPS interventions in addition to conventional infection-control managements. The number of CLABSIs patients, incidence of CLABSIs, average length of hospital stay, average total hospitalization cost, and disease outcomes were compared between the two groups. The intervention group had a significant reduction in the number and incidence of CLABSIs (0[0%] vs. 4[1.33%], P < 0.05). Two of the four patients with CLABSIs in the control group died. The average length of hospital stay was significantly longer in the control group than the intervention group (17 days vs. 13 days, P < 0.001). The average hospitalization cost in the control group was much higher than that in the intervention group (92.8 thousand yuan vs. 65.2 thousand yuan, P < 0.001). Patient outcome was improved in the intervention group than the control group (P = 0.001). In summary, the MDCIPS model effectively reduces the incidence of CLABSIs, alleviates the patients' economic burden, and improves the clinical outcomes of the patients.

The online version contains supplementary material available at 10.1007/s12288-024-01760-8.

Prognostic Utility of a Novel Prognostic Model Consisting of Age, CRP, Ki67, and POD24 in Patients with Angioimmunoblastic T-Cell Lymphoma.

Indian Journal Hematology Blood Transfusion

To find the independent factors affecting the prognosis of AITL patients, establish a novel predictive model, and stratify the prognosis of AITL patients. We retrospectively analyzed the clinical data of 86 patients diagnosed with AITL in the First Affiliated Hospital of Wenzhou Medical University from December 2010 to March 2022. The clinical features, recurrence time, and death time of patients were collected and analyzed statistically. The median age of our patients was 68 years old, and the male-to-female ratio was 2.2: 1. There are differences between males and females in ECOG PS score (p = 0.037), β2 microglobulin levels (p = 0.018) and IgM (p = 0.021). Multivariate COX regression analysis showed that C-reactive protein > 39.3 mg/L (hazard ratio (HR), 5.41; p = 0.0001), Age > 66 years (hazard ratio (HR), 3.06; p = 0.0160), Ki67 positive (hazard ratio (HR), 4.86; p = 0.0010) and early progression of disease within 24 months (POD24) after diagnosis (hazard ratio (HR), 12.47; p = 0.0001) were independent factors affecting the prognosis of OS. KM analysis showed that the predictive model established by these four factors could effectively predict the prognosis of patients with AITL (p < 0.0001), and the ROC curve showed that the predictive ability of the new predictive model (AUC = 0.909) was significantly better than that of the traditional predictive models, such as IPI (AUC = 0.730), PIT (AUC = 0.720), PIAI (AUC = 0.715) and AITL score (AUC = 0.724). Age, C-reactive protein, Ki67, and POD24 were independent factors affecting the prognosis of OS. The prognostic model established by them combined clinical features, and serological and pathological indicators and could effectively predict the prognosis of AITL patients.

The online version contains supplementary material available at 10.1007/s12288-024-01767-1.

A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience.

Indian Journal Hematology Blood Transfusion

CML is a commonly diagnosed myeloproliferative neoplasm in India. Tyrosine kinase inhibitors (TKIs) are the current standard of care for management...